Endpoints and follow-up
The primary endpoint of our study was freedom from any AF/atrial tachycardia episode lasting more than 30 seconds after the endo-/epicardial CA. AF/atrial tachycardia occurring within the first three month after the procedure (also known as “blanking period”) were not counted in the primary outcome analysis, in accordance with existing guidelines.2 The secondary endpoint was the change in the European Heart Rhythm Association (EHRA) score over follow-up. Patients were followed by symptoms, ECG, and 24-hour Holter monitor recordings one, three, six, nine, and twelve months after CA; furthermore, arrhythmia recurrences were assessed by implantable loop recorders or pacemakers/defibrillators with atrial leads, when available.